Compare ATOM & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | NSPR |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 81.8M |
| IPO Year | 2016 | N/A |
| Metric | ATOM | NSPR |
|---|---|---|
| Price | $2.20 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 417.2K | 58.9K |
| Earning Date | 02-10-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $38,000.00 | ★ $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | $300.00 | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $1.89 | $1.59 |
| 52 Week High | $17.55 | $3.80 |
| Indicator | ATOM | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 45.56 |
| Support Level | $2.17 | $1.89 |
| Resistance Level | $2.30 | $2.17 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 13.39 | 39.53 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used transistor types in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, logic and processors, and SRAM.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.